CompletedNCT04080752
A Study of JNJ-61393215 in the Treatment of Depression
This study evaluated the safety and effectiveness of JNJ-61393215 for people with depression.
Medication studyAges 18–64Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of JNJ-61393215 for people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Garden Grove and 34 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: September 17, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 222
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, United Kingdom, Moldova, ...
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT04080752
- Official title
Show the full official title
Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-61393215 as Adjunctive Treatment in Adults With Major Depressive Disorder With Anxious Distress With Suboptimal Response to Standard Antidepressants
Get this study by email
Recruitment & locations
CompletedGarden Grove, United States · Alpharetta, United States · Atlanta, United States
30 more locations
- New York, United States
- Staten Island, United States
- Columbus, United States
- Oklahoma City, United States
- Media, United States
- Dallas, United States
- Chisinau, Moldova
- Moscow, Russia
- Nizny Novgorod, Russia
- Orenburg, Russia
- Rostov-on-Don, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Saratov Region, Russia
- St.Peterburg, Russia
- Stavropol, Russia
- Tomsk, Russia
- Hlevakha, Ukraine
- Ivano-Frankivsk, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kyiv, Ukraine
- Nove, Ukraine
- Smila, Ukraine
- Vinnytsia, Ukraine
- Barnsley, United Kingdom
- Liverpool, United Kingdom
- London, United Kingdom
- Manchester, United Kingdom
- Russia
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of JNJ-61393215 for people with depression.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including JNJ-61393215 and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
